Isoflurane, Laparoscopic Cholecystectomy, Oxidative Stress, Sevoflurane
Conditions
Brief summary
The primary aim of this work is to assess the impact of exposure to isoflurane or sevoflurane as an inhalation anesthetic on the oxidative stress and inflammatory conditions in patients undergoing elective moderate invasive surgery (laparoscopic cholecystectomy).
Detailed description
Oxidative stress is defined as an imbalance between oxidants and antioxidants in favour of the oxidants, leading to a disruption of redox signalling and control and/or molecular damage. Isoflurane, which has been utilized since the 1980s, has a particularly low metabolism rate and solubility, leading to reduced induction of anesthesia during surgery and shortened recovery time after surgery. Sevoflurane began to be used a decade later and has a lower blood-gas partition coefficient than the other anesthetics, leading to rapid induction of anesthesia and fast awakening after anesthesia.
Interventions
DRUGIsoflurane
Patients will receive general anesthesia and maintenance by isoflurane.
DRUGSevoflurane
Patients will receive general anesthesia and maintenance by sevoflurane.
Sponsors
Ain Shams University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Age from 20 to 60 years. * Both sexes. * American Society of Anesthesiologists (ASA) Physical Status I-II. * Undergoing elective laparoscopic cholecystectomy under general anesthesia.
Exclusion criteria
* Refusal of participation in the study by patients. * Diabetes (type I or II), endocrine system, and immune system diseases. * Chronic infection and sepsis. * Cardiac condition as classified bythe New York Heart Association (NYHA) \> class II. * Hepatic disease: INR \> 1.5, and/or albumin \< 2.5 g/dL. * Renal disease: glomerular filtration rate (GFR) \< 85 ml/min. * Mental and neurological disorders.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum level of superoxide dismutase | 6 months postoperatively | Serum level of superoxide dismutase (SOD) will be recorded. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum level of serum soluble programmed cell death-ligand 1 | 6 months postoperatively | Serum level of serum soluble programmed cell death-ligand 1 (sPD-L1) will be recorded. |
| Serum level of nuclear factor erythroid 2-related factor | 6 months postoperatively | Serum level of nuclear factor erythroid 2-related factor (Nrf2) will be recorded. |
Countries
Egypt
Contacts
Primary ContactEman A Ali, Master
Outcome results
None listed